A study enrolling 1,443 stage I–IV CRC patients revealed that the prevalence of MSI-high, BRAF mutations, and CIMP-high tumors rapidly decreased from the proximal colon to the rectum (51). The gene discussed is BRAF; the disease is colorectal carcinoma.